These fast-growing companies have new personnel announcements to share. Photos courtesy

Three Houston startups have new hires they're excited about. From new board members to C-level execs, here's who's moving and shaking in Houston innovation.

Software company hires new product exec

Photo courtesy of Cart.com

Cart.com, an end-to-end e-commerce services provider, announced Michael Svatek as the company's first chief product officer. Formerly, Svatek served as chief product and strategy officer at Bazaarvoice and then co-founded and served as the CEO and head of product at Rivet Works, a cloud software platform.

"Michael's deep expertise across the e-commerce technology value chain coupled with his experience in M&A, strategic alliances, and entrepreneurship are one-of-a-kind in this industry, and a testament to our growth and trajectory at Cart.com," says Omair Tariq, Cart.com co-founder and CEO, in a news release. "We are so pleased to welcome Michael, a proven leader with an innate understanding of the Cart.com mission to unify and streamline the fragmented e-commerce value chain for brands of any size."

Earlier this year, Cart.com raised a $25 million series A funding round and emerged from stealth mode.

Fast-growing e-commerce startup lawyers up

Photo courtesy of GoExpedi

Houston-based GoExpedi, another tech company disrupting e-commerce, once again expanded its executive board, naming Julie Gremillion as general counsel. She has more than 10 years of experience in working with energy companies, and will lead the company's legal strategy, managing compliance and risk throughout the organization, and more.

"We are thrilled to have found Julie, one of the most experienced, savvy and well-rounded legal counsels in the industry," says Tim Neal, GoExpedi CEO, in a news release. "Her legal background in the energy space is beyond reproach. As we enter this next critical phase of growth, Julie's combined commercial and legal expertise will provide us with a platform for long-term and sustainable success."

GoExpedi also recently fundraised a $25 million round last fall.

Recently acquired therapeutics company adds board member

Photo via aiche.org

Clinical-stage biotechnology company, Coya Therapeutics Inc. has appointed Ann Lee., senior vice president of Cell Therapy Development and Operations at Bristol Myers Squibb, to the company's board of directors.

"Dr. Lee is one of the leading cell therapy technical development, supply chain and manufacturing executives in the biopharmaceutical industry," says Howard Berman, Coya CEO, says in a release. "At Coya, we are revolutionizing cell therapy manufacturing and supply chain management via proprietary cryopreservation to overcome prior limitations of Treg cell therapies. Dr. Lee's expertise will be instrumental as we advance in the clinic and build out manufacturing partnerships."

The company, which focuses on creating therapeutics for neurodegenerative and autoimmune diseases, announced earlier this year that it has completed a merger with Nicoya Health Inc. and raised $10 million in its series A.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”